Abarelix
| This article does not cite any references or sources. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (August 2011) |
| Systematic (IUPAC) name | |
|---|---|
| acetyl-D-β-naphthylalanyl- D-4-chlorophenylalanyl-D-3-pyridylalanyl-L-seryl-L- N-methyl- tyrosyl-D-asparagyl-L-leucyl-L-N(e )-isopropyl-lysyl-L-prolyl-D-alanyl-amide | |
| Clinical data | |
| AHFS/Drugs.com | monograph |
| Pregnancy cat. | ? |
| Legal status | ? |
| Pharmacokinetic data | |
| Protein binding | 96–99% |
| Identifiers | |
| CAS number | 183552-38-7 |
| ATC code | L02BX01 |
| PubChem | CID 16131215 |
| IUPHAR ligand | 1188 |
| DrugBank | BTD00051 |
| ChemSpider | 10482301 |
| UNII | W486SJ5824 |
| KEGG | D02738 |
| ChEBI | CHEBI:337298 |
| ChEMBL | CHEMBL1252 |
| Chemical data | |
| Formula | C72H95ClN14O14 |
| Mol. mass | 1416.06 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| |
|
Abarelix is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist). It is primarily used in oncology to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available. It belongs to the family of drugs called Gonadotropin-releasing hormone antagonists.
It is marketed by Speciality European Pharma as Plenaxis. Plenaxis has received marketing authorisation in Germany.
|
|||||||||||||||||||||
| This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
| This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |